Lorraine Marie Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lorraine Marie Chung has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Gopakumar Hariharan
Mackay Base Hospital
2 shared publications - Suraj Varma
MonashHeart & Monash Children's Hospital Monash Health Melbourne Victoria Australia
1 shared publication
Latest Publications
- 15 February 2023
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 59 (3) , 580-588
Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart disease
Aim: To review current literature regarding the safety of stimulant medications for treatment of attention deficit hyperactivity disorder in paediatric congenital heart disease (CHD) patients.Methods: Embase, MEDLINE complete, CINAHL complete and Psychology and Behavioural Sciences Collection were searched for relevant articles from January 1980 to July 2022.Results: One hundred and three articles were identified during the initial search after removal of duplicates. Thirty‐five articles were selected for review and 11 were included as relevant to the clinical question.Conclusions: Stimulant medications are safe in patients with underlying CHD. In mild congenital cardiac conditions (ventricular septal defect, atrial septal defect and isolated semilunar valve disease), paediatricians can safely initiate stimulant therapy. With complex CHD cases, cardiology opinion is recommended prior to starting stimulants.
- 15 February 2023
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 59 (3) , 580-588
Safety of stimulant medications for attention deficit hyperactivity disorder in paediatric congenital heart disease
Aim: To review current literature regarding the safety of stimulant medications for treatment of attention deficit hyperactivity disorder in paediatric congenital heart disease (CHD) patients.Methods: Embase, MEDLINE complete, CINAHL complete and Psychology and Behavioural Sciences Collection were searched for relevant articles from January 1980 to July 2022.Results: One hundred and three articles were identified during the initial search after removal of duplicates. Thirty‐five articles were selected for review and 11 were included as relevant to the clinical question.Conclusions: Stimulant medications are safe in patients with underlying CHD. In mild congenital cardiac conditions (ventricular septal defect, atrial septal defect and isolated semilunar valve disease), paediatricians can safely initiate stimulant therapy. With complex CHD cases, cardiology opinion is recommended prior to starting stimulants.
- 7 February 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (4) , 885-886
EBNEO Commentary: Safety and efficacy of erythropoietin in neonates with hypoxic–ischaemic encephalopathy
- 7 February 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (4) , 885-886
EBNEO Commentary: Safety and efficacy of erythropoietin in neonates with hypoxic–ischaemic encephalopathy